Respiratory Failure Deaths With Atrial Fibrillation Climbed Sharply Across 25 Years
Mortality involving respiratory failure and co-listed atrial fibrillation/flutter rose steeply among U.S. adults aged 65 years and older between 1999 and 2024, with the burden accelerating during the COVID-19 era and then easing only partially. The national pattern is difficult to dismiss: deaths rose to 433,598 over the study period, and the age-adjusted mortality rate increased from 12.8 per 100,000 in 1999 to 66.7 per 100,000 in 2024.
This is not a small drift in coding statistics. It describes a more than fivefold rise in a combined cardiopulmonary mortality signal among older adults, a population already vulnerable to decompensation when chronic heart rhythm disease collides with acute or chronic respiratory illness.
The analysis used CDC WONDER multiple cause-of-death data, capturing deaths in which ICD-10 codes for respiratory failure and atrial fibrillation or flutter appeared together. Rates were standardized to the 2000 U.S. population and examined across sex, race and ethnicity, region, urbanization, state, and place of death. Joinpoint regression identified a long initial climb, a sharper surge beginning in the late 2010s, and a decline after 2021 that did not erase the preceding rise. Forecasting through 2035 projected continued growth, with an age-adjusted mortality rate of 122.96 per 100,000 by 2035.
The Pandemic Period Separated the Curve Into Distinct Phases
Three temporal segments define the trajectory. From 1999 to 2018, the rate increased steadily, with an annual percent change of 7.73%. From 2018 to 2021, the slope steepened dramatically to 18.10% per year. After 2021, the curve turned downward, with a -5.25% annual percent change through 2024.
The spike during the COVID-19 period is biologically plausible. Severe respiratory infection, hypoxemia, systemic inflammation, and intensive-care interventions all strain atrial electrophysiology and ventricular filling. In older adults, atrial fibrillation can lower cardiac output and worsen pulmonary congestion, while respiratory failure itself can trigger arrhythmia through hypoxia, catecholamine surges, acid-base derangements, and mechanical ventilation stress. When both conditions are present on the death certificate, they may reflect a terminal cardiopulmonary cascade rather than isolated organ failure.
The downturn after 2021 should be read cautiously. A partial decline does not reverse a quarter-century increase, and it does not mean the underlying risk has normalized.
Men, White Adults, and the Midwest Carried the Highest Burden
Sex-stratified patterns showed consistently higher mortality among men than women. Males had both a higher age-adjusted mortality rate and a steeper increase across time, with an average annual percent change of 8.44% compared with 7.81% in females. That gap fits broader clinical experience: older men often arrive with heavier cardiovascular disease burden, more advanced structural heart disease, and a higher prevalence of long-standing atrial arrhythmia complications.
Racial and ethnic differences were also marked. Non-Hispanic White adults had the highest mean age-adjusted mortality rate, while Hispanic adults experienced the largest relative increase over time, with an AAPC of 8.72%. Non-Hispanic Asian/Pacific Islander adults had the smallest increase, with an AAPC of 6.23%. These differences are unlikely to arise from one mechanism alone. Access to chronic rhythm management, pulmonary care, anticoagulation, comorbidity control, and timely inpatient rescue probably all contribute, alongside differences in population age structure and underlying disease prevalence.
Regional variation was equally striking. The Midwest showed the fastest growth, with an AAPC of 9.35%. State-level rates ranged from 24.7 in Ohio to 85.1 in Louisiana. Such spread suggests that geography matters at the level of health systems, comorbidity profiles, environmental exposures, and care access. Older adults in non-metropolitan areas also experienced faster growth than those in metropolitan areas from 1999 to 2020, with AAPCs of 10.09% and 8.21%, respectively.
Hospital Deaths Dominated, Pointing to Late and Severe Decompensation
Most deaths occurred in hospital inpatient settings, accounting for 64.1% of the total. Nursing homes contributed 14.1%, and home deaths accounted for 11.9%.
Hospital predominance suggests that this combined diagnosis often marks severe illness requiring escalation beyond outpatient management. In practical terms, respiratory failure with atrial fibrillation is rarely a quiet endpoint. It frequently develops in the setting of pneumonia, fluid overload, chronic obstructive lung disease, heart failure, sepsis, or frailty, where rhythm instability can make oxygen delivery even less efficient. The atrial loss of coordinated contraction may be especially consequential in older hearts with stiff ventricles, where preload dependence is high and small hemodynamic changes produce large clinical effects.
The place-of-death distribution also implies that prevention may need to happen earlier in the disease course. Once an older patient reaches the inpatient phase with both respiratory failure and atrial fibrillation in play, the window for reversing the trajectory has already narrowed.
Forecasts Through 2035 Suggest the Problem Will Persist
The model projected a continued rise to 122.96 per 100,000 by 2035, with a wide prediction interval from 85.42 to 160.50. Forecasts of this kind cannot account for every future change in treatment, vaccination, care access, coding, or population health, yet they provide a warning that the underlying burden may remain substantial if present patterns continue.
For clinicians, the implication is straightforward. Older adults with atrial fibrillation should not be viewed only through a stroke-prevention lens; respiratory reserve, infection vulnerability, heart failure burden, and overall frailty deserve equal attention. Likewise, adults presenting with respiratory failure warrant rhythm assessment, especially when tachyarrhythmia may be worsening oxygen demand and impairing circulation.
The analysis is limited by its reliance on death certificate data, which cannot prove causation and may miss clinical nuance such as whether atrial fibrillation was chronic, new, or merely listed in association with terminal illness. Coding practices may also shift across years and regions. Even with those caveats, the pattern is too large to ignore: older Americans died more often with respiratory failure and atrial fibrillation listed together, the increase was uneven across demographic groups, and the projected curve remains upward rather than flat.